The CNTO 95 human antibody was generated using Medarex’s UltiMAb technology. Medarex may receive future milestone payments and royalties should this product candidate progress to commercialization and achieve commercial sales.
Howard Pien, president and CEO of Medarex, said: “We are pleased with the progress of this program and the potential of technology licensing programs under our partnership with Centocor to contribute to future revenues.”